The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension.After a 4-week placebo period, 74 adult outpatients with essential hypertension (diastolic blood pressure [DBP] >90 and <110 mmHg, and systolic blood pressure [SBP] >140 mmHg) were treated with A 10 mg once daily for 4 weeks. Thereafter, nonresponder patients (DBP >90 mmHg and/or SBP >140 mmHg; n=51) were randomized to receive additional V 160 mg once daily or O 20 mg once daily for 8 weeks in two crossover periods, each separated by a 4-week placebo period. Clinic blood pressure (BP), heart rate, and ankle/foot volume (AFV) were evaluated and blood samples were drawn to evaluate plasma norepinephrine (NE) levels.Both V/A and O/A induced a greater SBP/DBP reduction than A monotherapy (-26.4/-20.8 mmHg and -24.4/-19.1 mmHg, respectively; all P<0.001 vs. baseline and P<0.01 vs. A). A monotherapy increased AFV by 24\%, P<0.001 vs. baseline, while the addition of either V or A reduced such increases. However, with V/A the AFV increase (+9.7\%, P<0.05 vs. baseline, P<0.01 vs. A) was lower than with O/A (+16.7\%, P<0.01 vs. baseline, P<0.05 vs. A); the difference between the two combinations was significant. Plasma NE levels were significantly increased by A (+44.6\%) and values did not change with the addition of V (+35.2\%) or O (+33.7\%). Plasma active renin (PAR) was unchanged by A but increased by V/A (+214.4\%, P<0.05 vs. baseline) and further by O/A (+325.6\%, P<0.01 vs. baseline; difference between the 2 combinations: P<0.05). An inverse correlation was found between the AFV decrease and PAR increase (r=-0.31, P<0.05).Adding V or O to A reduced ankle edema, but this effect was more pronounced with V. The greater degree of renin-angiotensin system activation observed with Ocould be related to such a difference.

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients

FOGARI, ROBERTO;Mugellini A;PRETI, PAOLA STEFANIA;DEROSA, GIUSEPPE
2010-01-01

Abstract

The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension.After a 4-week placebo period, 74 adult outpatients with essential hypertension (diastolic blood pressure [DBP] >90 and <110 mmHg, and systolic blood pressure [SBP] >140 mmHg) were treated with A 10 mg once daily for 4 weeks. Thereafter, nonresponder patients (DBP >90 mmHg and/or SBP >140 mmHg; n=51) were randomized to receive additional V 160 mg once daily or O 20 mg once daily for 8 weeks in two crossover periods, each separated by a 4-week placebo period. Clinic blood pressure (BP), heart rate, and ankle/foot volume (AFV) were evaluated and blood samples were drawn to evaluate plasma norepinephrine (NE) levels.Both V/A and O/A induced a greater SBP/DBP reduction than A monotherapy (-26.4/-20.8 mmHg and -24.4/-19.1 mmHg, respectively; all P<0.001 vs. baseline and P<0.01 vs. A). A monotherapy increased AFV by 24\%, P<0.001 vs. baseline, while the addition of either V or A reduced such increases. However, with V/A the AFV increase (+9.7\%, P<0.05 vs. baseline, P<0.01 vs. A) was lower than with O/A (+16.7\%, P<0.01 vs. baseline, P<0.05 vs. A); the difference between the two combinations was significant. Plasma NE levels were significantly increased by A (+44.6\%) and values did not change with the addition of V (+35.2\%) or O (+33.7\%). Plasma active renin (PAR) was unchanged by A but increased by V/A (+214.4\%, P<0.05 vs. baseline) and further by O/A (+325.6\%, P<0.01 vs. baseline; difference between the 2 combinations: P<0.05). An inverse correlation was found between the AFV decrease and PAR increase (r=-0.31, P<0.05).Adding V or O to A reduced ankle edema, but this effect was more pronounced with V. The greater degree of renin-angiotensin system activation observed with Ocould be related to such a difference.
2010
The Cardiovascular & Respiratory Systems category covers resources concerned with all aspects of cardiovascular and thoracic surgery and respiratory diseases. Topics include circulation, cardiovascular technology and measurement, cardiovascular pharmacology and therapy, hypertension, heart and lung transplantation, arteries, arteriosclerosis, thrombosis, angiology, perfusion, stroke, as well as all types of respiratory and lung diseases.
Sì, ma tipo non specificato
Inglese
Internazionale
ELETTRONICO
27
48
55
7
Adult, Aged, Amlodipine; therapeutic use, Ankle Joint, Antihypertensive Agents; administration /&/ dosage/therapeutic use, Blood Pressure, Cross-Over Studies, Drug Therapy; Combination, Edema; drug therapy, Female, Heart Rate; drug effects, Humans, Hypertension; drug therapy, Imidazoles; administration /&/ dosage/therapeutic use, Male, Middle Aged, Norepinephrine; blood, Prospective Studies, Tetrazoles; administration /&/ dosage/therapeutic use, Valine; administration /&/ dosage/analogs /&/ derivatives/therapeutic use
http://dx.doi.org/10.1007/s12325-010-0002-0
7
info:eu-repo/semantics/article
262
Fogari, Roberto; Malamani, G; Corradi, L; Mugellini, A; Preti, PAOLA STEFANIA; Zoppi, A; Derosa, Giuseppe
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/378979
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact